Historical review from 2026-11-12. Current price and availability are unconfirmed; check the original marketplace.
Stacker is a niche health-tracking app with exceptional 98% profit margins and a 2.88x annual profit multiple—metrics that would normally merit strong consideration. However, the $442/mo revenue is below the threshold for meaningful cash flow evaluation, and the absence of customer count, retention data, or growth trajectory makes it impossible to assess business durability or acquisition value. The extreme margin suggests minimal ongoing costs rather than a scalable, profitable operation; this warrants direct clarification with the seller before serious evaluation.
Stacker is a single-platform (iOS) health tracker with standard features: user authentication, dose logging, reminders, and simple progress tracking. These components can be built rapidly using SwiftUI templates, Firebase for backend, and third-party reminder/notification libraries. At $15,000 asking price for $434/mo profit and no demonstrated customer traction, user count, or retention metrics, the acquisition risk is substantial relative to the reproducible software scope. A solo founder with an AI coding subscription could build a competitive MVP in 6–8 weeks for $3,500–$7,500 in cash. The purchase does not include verified paying customers, organic distribution, or durable revenue history—only an app binary and source code. Build is the lower-risk path unless the seller can demonstrate a meaningful, retained customer base and documented monthly revenue stability over time.
Cash estimate includes the AI tools, APIs and infrastructure needed for a solo founder to recreate the software. Build time is informational and lightly weighted. The verdict is driven mainly by customers, users, verified earnings, retention, distribution, brand, data and operating history.
Helps users build personalized peptide stacks, log doses, get reminders, and track protocol progress and results in one iPhone app.
Opens the original listing on TrustMRR
Get new listings with asking prices, monthly profit, deal scores, and key risks.
The best reviewed deals, concise and evidence-first. Unsubscribe anytime.
Preliminary screening based on marketplace and public data. Verify all financial, legal, technical, customer, and operational claims independently before making an acquisition decision. This is not financial or legal advice.